Severe Gastrointestinal Mucositis Following Concurrent Palbociclib and Palliative Radiation Therapy.

Background/aim: Palbociclib is an FDA-approved cyclin-dependent kinase inhibitor for the treatment of advanced breast cancer. Limited information is available regarding the toxicity of palbociclib and concurrent radiation therapy.

Case Report: Herein, we report a case of esophageal toxicity in a patient treated with palbociclib and radiation therapy.